Neurocrine Biosciences is a biopharmaceutical company that specializes in developing treatments for endocrine disorders and diseases. Neurocrine Biosciences has three late-stage products which focus on women’s health, Parkinson’s disease, and Tourette syndrome. There is a large addressable market for these health conditions and FDA approvals will undoubtedly boost the long term prospects of Neurocrine Biosciences.
The long term monthly chart for Neurocrine Biosciences shows a steady uptrend with major corrections in late 2018, early 2020, and mid-2020. After the first two falls, the price has risen back up. The level around $85 has proven to be an important resistance level in 2019 and then a support in 2020. Currently, prices are finding support again around the $85 level (as well as the bottom of the long term trend) and look poised to go back up to around $140. A stop loss can be placed below the support-resistance level, somewhere near $82.
Position entered to our long term tracking portfolio today. The entry point is at $94.57 and stop loss $70.70 which is 25% below the entry point. The short-term to medium take profit is set at $149 giving a profit of 58%.
On the video and images above you will see the reason this stock was selected.
You will see the image is of a monthly chart of the stock showing the long-term upwards trend formed over the years. You will also see the entry point and the where the stop loss is placed. For more information please watch the video given.
Once it is time to move the original stop loss up you will see an additional image.